Genocea Biosciences (NASDAQ:GNCA) Now Covered by StockNews.com
by Jessica Moore · The Cerbat GemInvestment analysts at StockNews.com initiated coverage on shares of Genocea Biosciences (NASDAQ:GNCA – Get Free Report) in a research report issued on Thursday. The firm set a “sell” rating on the biotechnology company’s stock.
Genocea Biosciences Stock Performance
The company has a market capitalization of $6,000.00, a P/E ratio of 0.00 and a beta of 1.61. The company has a current ratio of 1.35, a quick ratio of 1.35 and a debt-to-equity ratio of 0.24. Genocea Biosciences has a twelve month low of $0.00 and a twelve month high of $0.00.
About Genocea Biosciences
Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor.
Read More
- Five stocks we like better than Genocea Biosciences
- Business Services Stocks Investing
- Archer Aviation’s Africa Deal Could Boost ACHR Stock
- High Flyers: 3 Natural Gas Stocks for March 2022
- Are Short Sellers Wrong About These 3 Semiconductor Stocks?
- Differences Between Momentum Investing and Long Term Investing
- Boeing Gets $50B in March Orders—Is BA Stock a Buy Now?